Kyowa Kirin (KYKOF) Projected to Release Quarterly Earnings on Monday

Kyowa Kirin (OTCMKTS:KYKOF) is expected to post its results after the market closes on Monday, November 2nd. Analysts expect Kyowa Kirin to post earnings of $0.2511 per share and revenue of $796.43 million for the quarter.

Kyowa Kirin Stock Performance

KYKOF stock opened at $16.75 on Friday. The firm has a 50 day simple moving average of $14.93 and a 200 day simple moving average of $14.61. Kyowa Kirin has a 52 week low of $4.20 and a 52 week high of $16.75.

Analyst Ratings Changes

Separately, Jefferies Financial Group lowered shares of Kyowa Kirin to a “hold” rating in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Kyowa Kirin Company Profile

Kyowa Kirin Co, Ltd. is a Japan-based specialty pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses on therapies for areas including oncology, immunology, nephrology, the central nervous system and rare diseases, with an emphasis on biologics and other innovative treatments.

Its products include Poteligeo (mogamulizumab), an antibody used in certain hematologic cancers and cutaneous T-cell lymphomas, and Crysvita (burosumab), a treatment for disorders involving abnormal phosphate regulation.